InsiderTrades.com logo
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.

Joseph Zakrzewski Biography and Net Worth

Director of Amarin
  • Phone
  • Email
  • Website


Joseph S. Zakrzewski joined Amarin in January 2010 as Executive Chairman and served as Amarin’s CEO from November 2010 until the end of December 2013 when he retired from his executive roles and while remaining as a member of the Board of Directors. Mr. Zakrzewski has more than 20 years of industry experience, including significant contributions to Reliant Pharmaceuticals as Chief Operating Officer during the period when Omacor®/Lovaza® was successfully developed, launched, and marketed for reducing very high triglyceride levels, leading to its 2007 acquisition by GlaxoSmithKline. In addition, Mr. Zakrzewski contributed 17 years of service to Eli Lilly & Company in a variety of capacities, including Vice President of Corporate Business Development where he had global responsibility for licensing activities. Mr. Zakrzewski also serves on the Boards of Acceleron Pharma and Insulet Corporation.

What is Joseph S. Zakrzewski's net worth?

The estimated net worth of Joseph S. Zakrzewski is at least $202,940.00 as of January 18th, 2024. Mr. Zakrzewski owns 405,880 shares of Amarin stock worth more than $202,940 as of November 16th. This net worth evaluation does not reflect any other investments that Mr. Zakrzewski may own. Learn More about Joseph S. Zakrzewski's net worth.

How do I contact Joseph S. Zakrzewski?

The corporate mailing address for Mr. Zakrzewski and other Amarin executives is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. Amarin can also be reached via phone at (531) 669-9020 and via email at [email protected]. Learn More on Joseph S. Zakrzewski's contact information.

Has Joseph S. Zakrzewski been buying or selling shares of Amarin?

Joseph S. Zakrzewski has not been actively trading shares of Amarin during the last ninety days. Most recently, on Tuesday, December 14th, Joseph S. Zakrzewski bought 10,000 shares of Amarin stock. The stock was acquired at an average cost of $3.27 per share, with a total value of $32,700.00. Learn More on Joseph S. Zakrzewski's trading history.

Who are Amarin's active insiders?

Amarin's insider roster includes Michael Kalb (CFO), Joseph Kennedy (General Counsel), Steven Ketchum (Insider), David Stack (Director), and Joseph Zakrzewski (Director). Learn More on Amarin's active insiders.

Are insiders buying or selling shares of Amarin?

During the last twelve months, Amarin insiders bought shares 2 times. They purchased a total of 174,426 shares worth more than $118,124.34. During the last twelve months, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 34,131 shares worth more than $26,963.49. The most recent insider tranaction occured on August, 2nd when CEO Aaron Berg bought 160,000 shares worth more than $102,400.00. Insiders at Amarin own 2.0% of the company. Learn More about insider trades at Amarin.

Information on this page was last updated on 8/2/2024.

Joseph S. Zakrzewski Insider Trading History at Amarin

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2021Buy10,000$3.27$32,700.00View SEC Filing Icon  
7/5/2019Sell100,000$23.82$2,382,000.00View SEC Filing Icon  
6/18/2019Sell100,000$19.02$1,902,000.00View SEC Filing Icon  
1/2/2019Sell526,500$13.07$6,881,355.00View SEC Filing Icon  
9/24/2018Sell500,000$10.60$5,300,000.00View SEC Filing Icon  
See Full Table

Joseph S. Zakrzewski Buying and Selling Activity at Amarin

This chart shows Joseph S Zakrzewski's buying and selling at Amarin by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amarin Company Overview

Amarin logo
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $0.50
Low: $0.50
High: $0.52

50 Day Range

MA: $0.59
Low: $0.50
High: $0.63

2 Week Range

Now: $0.50
Low: $0.50
High: $1.37

Volume

2,005,382 shs

Average Volume

1,531,844 shs

Market Capitalization

$205.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.